Retrospective Observational Study to Observe Clinical Effectiveness of Add-on Canagliflozin 100 mg in Indian Type 2 Diabetes Patients with BMI>25 kg/m<sup>2</sup>, in Real World Clinical Setting- A Specialized Population of Group A/B Officers Employees of

Abstract

With the changing life style in the recent decade risk of chronic non-communicable diseases (NCDs) like diabetes has increased globally. World Health Organization (WHO) projections show that NCDs will be responsible for a significantly increased number of deaths in the next decade, especially in urban sedentary population. We planned to assess GROUP A/B OFFICERS EMPLOYEES OF FINANCIAL AND PUBLIC SECTORS (nationalized banks, insurance sector, government and semi-government PCUS), as they belong to special workgroup who predominantly have sedentary life style [1]. The prevalence of sedentary lifestyle among bankers is high and as it kills some 5.3 million people every year, according to the WHO, and with the increase and aging of the population, these lifestyles will become increasingly more common in low- and middle-income countries like India. Lifestyles with little or no physical activity are the leading cause of obesity, and one of the main risk factors for diabetes and cardiovascular disease. According to the International labor organization (ILO), people who engage in little physical activity run a 20% or 30% greater risk of dying from above causes. [2] Sodium-glucose linked transporter (SGLT) type2 inhibitors, constituting the most recently available oral glucose-lowering drug category, exert their effect by increasing urinary glucose excretion. Optimal prescribing of agents within this category requires a full understanding of their risks in addition to their benefits. Besides improving glycaemia control, weight and blood pressure some members of this class provide beneficial cardiovascular and Reno protective Effects. [7, 13] So the present retrospective observational study was aimed to observe clinical effectiveness of add-on Canagliflozin 100 mg in high risk sedentary population i.e. uncontrolled Indian Type 2 Diabetes mellitus (Type2DM) Patients with body mass index (BMI) >25 kg/m2, includes group A/B officer employees of financial and public sectors who were already on other hypoglycemic, anti-hypertensive and lipid lowering agents. These data were analyzed over a period of 12 months (1 stJune2017-30may 2018) among above-said employees of various sectors in Jaipur. After Ethical clearances from institutional ethical committee, a total of 113 Type2DM participants were included at baseline, 13 were excluded from study and their annual health data's subsequently analyzed after add-on Canagliflozin 100 mg pre breakfast, with earlier pharmacological management with no dose adjustment during the entire period of study. Significant reduction glycated hemoglobin (HbA1c) was noted in, as we observed the target HbA1c near normal (p-<0.0001). Significant weight reduction was found in two sub-groups in our study (p< 0.0001). Significant reduction of Triglyceride was noted in all study groups (p-<0.0001), but same trend was not observed in LDL, HDL and TC, although reduction was definitely noted.